Scuola di Medicina e Chirurgia, Università Milano Bicocca, Monza, Italy.
Neurosciences Intensive Care Unit, John Radcliffe Hospital, Oxford, UK.
BMJ Open. 2019 Apr 20;9(4):e026552. doi: 10.1136/bmjopen-2018-026552.
Intracranial pressure (ICP) monitoring is commonly used in neurocritical care patients with acute brain injury (ABI). Practice about indications and use of ICP monitoring in patients with ABI remains, however, highly variable in high-income countries, while data on ICP monitoring in low and middle-income countries are scarce or inconsistent. The aim of the SYNAPSE-ICU study is to describe current practices of ICP monitoring using a worldwide sample and to quantify practice variations in ICP monitoring and management in neurocritical care ABI patients.
The SYNAPSE-ICU study is a large international, prospective, observational cohort study. From March 2018 to March 2019, all patients fulfilling the following inclusion criteria will be recruited: age >18 years; diagnosis of ABI due to primary haemorrhagic stroke (subarachnoid haemorrhage or intracranial haemorrhage) or traumatic brain injury; Glasgow Coma Score (GCS) with no eye opening (Eyes response=1) and Motor score ≤5 (not following commands) at ICU admission, or neuro-worsening within the first 48 hours with no eye opening and a Motor score decreased to ≤5. Data related to clinical examination (GCS, pupil size and reactivity, Richmond Agitation-Sedation Scale score, neuroimaging) and to ICP interventions (Therapy Intensity Levels) will be recorded on admission, and at day 1, 3 and 7. The Glasgow Outcome Scale Extended (GOSE) will be collected at discharge from ICU and from hospital and at 6-month follow-up. The impact of ICP monitoring and ICP-driven therapy on GOSE will be analysed at both patient and ICU level.
The study has been approved by the Ethics Committee 'Brianza' at the Azienda Socio Sanitaria Territoriale (ASST)-Monza (approval date: 21 November 2017). Each National Coordinator will notify the relevant ethics committee, in compliance with the local legislation and rules. Data will be made available to the scientific community by means of abstracts submitted to the European Society of Intensive Care Medicine annual conference and by scientific reports and original articles submitted to peer-reviewed journals.
NCT03257904.
颅内压(ICP)监测在患有急性脑损伤(ABI)的神经危重症患者中通常被应用。然而,在高收入国家,ICP 监测的适应证和使用仍然存在很大差异,而关于中低收入国家 ICP 监测的数据则很少或不一致。SYNAPSE-ICU 研究的目的是使用全球样本描述目前 ICP 监测的应用情况,并量化神经危重症 ABI 患者中 ICP 监测和管理的实践差异。
SYNAPSE-ICU 研究是一项大型的国际性、前瞻性、观察性队列研究。从 2018 年 3 月至 2019 年 3 月,所有符合以下纳入标准的患者将被招募:年龄>18 岁;诊断为原发性出血性卒中(蛛网膜下腔出血或颅内出血)或创伤性脑损伤导致的 ABI;格拉斯哥昏迷评分(GCS)无睁眼(眼睛反应=1)且在 ICU 入院时运动评分≤5(不遵嘱),或在最初 48 小时内神经恶化且无睁眼且运动评分下降至≤5。与临床检查(GCS、瞳孔大小和反应性、里士满躁动-镇静评分、神经影像学)和 ICP 干预(治疗强度水平)相关的数据将在入院时以及第 1、3 和 7 天记录。格拉斯哥结局量表扩展版(GOSE)将在 ICU 出院和出院后以及 6 个月随访时收集。将分析 ICP 监测和 ICP 驱动的治疗对 GOSE 的影响,既在患者层面也在 ICU 层面进行分析。
该研究已获得 Azienda Socio Sanitaria Territoriale(ASST)-Monza 的 Brianza 伦理委员会的批准(批准日期:2017 年 11 月 21 日)。每个国家协调员将根据当地法规和规则,通知相关伦理委员会。将通过提交给欧洲重症监护医学学会年会的摘要以及提交给同行评议期刊的科学报告和原始文章,向科学界提供数据。
NCT03257904。